Premium
Intravenous Levetiracetam as first‐line treatment of status epilepticus in the elderly
Author(s) -
Fattouch J.,
Di Bonaventura C.,
Casciato S.,
Bonini F.,
Petrucci S.,
Lapenta L.,
Manfredi M.,
Prencipe M.,
Giallonardo A. T.
Publication year - 2010
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2010.01351.x
Subject(s) - status epilepticus , medicine , concomitant , adverse effect , epilepsy , levetiracetam , anesthesia , electroencephalography , psychiatry
Fattouch J, Di Bonaventura C, Casciato S, Bonini F, Petrucci S, Lapenta L, Manfredi M, Prencipe M, Giallonardo AT. Intravenous Levtiracetam as first‐line treatment of status epilepticus in the elderly. Acta Neurol Scand: 2010: 121: 418–421.
© 2010 John Wiley & Sons A/S. Background – Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly. Treatment in the elderly can be complicated by serious side effects associated with traditional drugs. Objective – The aim of this pilot study was to evaluate the short‐term efficacy/safety of intravenously administered LEV (IVLEV) as the treatment of choice for SE in the elderly. Methods – We enrolled nine elderly patients (five female/four male; median age 78 years) with SE. Two patients had a previous diagnosis of epilepsy; in the remaining seven, SE was symptomatic. SE was convulsive in five and non‐convulsive in four. All the patients presented concomitant medical conditions (arrhythmias/respiratory distress/hepatic diseases). As the traditional therapy for SE was considered unsafe, IVLEV was used as first‐line therapy (loading dose of 1500 mg/100 ml/15 min, mean maintenance daily dose of 2500 mg/24 h) administered during video‐EEG monitoring. Results/conclusions – In all the patients but one, IVLEV was effective in the treatment of SE and determined either the disappearance of (7/8), or significant reduction in (1/8), epileptic activity; no patient relapsed in the subsequent 24 h. No adverse events or changes in the ECG / laboratory parameters were observed. These data suggest that IVLEV may be an effective/safe treatment for SE in the elderly.